October 2013, Volume 45, Issue 5, pp 1301-1308,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 07 Dec 2012
Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Intravenous cyclophosphamide (IVCY) has been used to treat severe lupus nephritis (LN) for many years. Because of the wide variety of manifestations of the condition and the long-term nature of the disease, outcomes vary widely.
To evaluate and compare the immediate and long-term results of IVCY in pediatric onset severe LN and between patients with normal and abnormal initial renal function.
Patients aged <18 years who attended the Department of Pediatrics, Prince of Songkla University, diagnosed with severe LN, and who were given a 36-month IVCY course, were included. Comparison of overall survival between the two groups was assessed using Kaplan–Meier survival curves.
108 patients with a mean age of 12.6 ± 2.7 years were studied, with a mean follow-up time of 5.7 ± 4.3 years. 48 patients completed the IVCY course. 36 patients had abnormal renal function and 72 patients had normal renal function at the start of therapy. Both groups responded well initially to treatment; proteinuria reduced to normal levels after 1 and 2 treatments in the normal and abnormal groups, respectively, while creatinine clearance returned to normal levels after 8 treatments in the abnormal group. Overall survival was not different between the two groups; however, the abnormal renal function group had a higher crude mortality rate than the normal group (13/36 vs 10/72, p value = 0.02). At the time of analysis, some patients who had completed their IVCY course still required other therapy to control their disease activity.
Three years of IVCY treatment provided similar outcomes in both normal and abnormal renal function groups. Immediate outcomes were favorable but long-term remission was not promising.
Austin HA, Balow JE (2000) Treatment of lupus nephritis. Semin Nephrol 20:265–276PubMed
Balow JE, Boumpas DT, Austin HA III (2000) New prospects for treatment of lupus nephritis. Semin Nephrol 20:32–39PubMed
Kim YG, Kim HW, Cho YM et al (2008) The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment. Rheumatology (Oxford) 47:311–314CrossRef
R Development Core Team. R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, Available at: www.R-project.org. [accessed 1 December 2010]
Al Salloum AA (2003) Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children. Pediatr Nephrol 18:357–361PubMed
Vachvanichsanong P, Dissaneewate P, McNeil E (2009) Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: a 23-year experience in a single centre. Nephrol Dial Transpl 24:2729–2734CrossRef
Mok CC, Ying KY, Ng WL et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119:355.e25–355.e33CrossRef
Cunha I, Saavedra MJ, Pereira da Silva JA et al (2008) Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus. Acta Reumatol Port 33:69–76PubMed
- Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
International Urology and Nephrology
Volume 45, Issue 5 , pp 1301-1308
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Lupus nephritis
- Systemic lupus erythematosus
- Intravenous cyclophosphamide
- Industry Sectors
- Author Affiliations
- 1. Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90110, Songkla, Thailand
- 2. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90110, Thailand